4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo

Cellular and Molecular Immunology

Volumn 5, Issue 5, 2008, Pages 379-384

  Li, Qiaoxia ^a   Ai, Jun ^a   Song, Zhenchuan ^a   Liu, Jie ^b   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Ninth Hospital of Shijiazhuang   (China)

Author keywords

4 1BBL; anti tumor; CTL; TIL

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; CD137 LIGAND; TNFSF9 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD137; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 65849212912     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2008.47     Document Type: Article

References (22)

1. Yoshida H, Katavose Y, Unno M, et al. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol Immunother. 2003;52:97-106. (Pubitemid 36337617)
2. Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB/4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004;11:215-226. (Pubitemid 38280524)
3. Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol. 2001;210:56-65. (Pubitemid 32756942)
4. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol. 2003;170:2912-2922. (Pubitemid 36302162)
5. Salih HR, Kosowski S G, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol. 2000;165:2903-2910. (Pubitemid 30660743)
6. Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther. 2005;12:1526-1533. (Pubitemid 41508678)
7. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumor and host cells. Immunology. 2000;101:541-547. (Pubitemid 32001469)
8. + T cells. Int Immunol. 2002;14:1155-1167. (Pubitemid 35175223)
9. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst. 2000;92:931-935.
10. Xiao H, Huang B, Yuan Y, et al. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res. 2007;13:1823-1830. (Pubitemid 46952952)
11. Huang BJ, Yin H, Huang YF, et al. Gene therapy using adenoviral vector encoding 4-1BBIg gene significantly prolonged murine cardiac allograft survival. Transpl Immunol. 2006;16:88-95.
12. Lu ZY, Condomines M, Tarte K, et al. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol. 2007;35:443-453.
13. Mizutani Y, Yoshida O, Miki T. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol. 1999;162:2170-2175.
14. Herd KA, Wiethe C, Tindle RW. Co-immunization with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules dose not enhance effector or memory CTL responses afforded by immunization with a tumor antigen-encoding DNA vaccine. Vaccine. 2007;25:5209-5219. (Pubitemid 46907375)
15. Bukczvnski J, Wen T, Wang C, et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol. 2005;175:6378-6389. (Pubitemid 41598878)
16. + memory T cells and their capacity for secondary expansion. J Immunol. 2005;175:1665-1676. (Pubitemid 41023070)
17. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227-238. (Pubitemid 37323223)
18. Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol. 1999;163:4859-4868. (Pubitemid 29501250)
19. Rabu C, Quemener A, Jacques Y, Echasserieau K, Vusio P, Lang F. Production of recombinant human trimetric CD137L (4-1BBL) cross-linking is essential to its T cell co-stimulation activity. J Biol Chem. 2005;280:41472-41481. (Pubitemid 41832207)
20. Bertram EM, Lau P, Watts TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol. 2002;168:3777-3785. (Pubitemid 34298377)
21. Cannons JL, Choi Y, Watts TH. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J Immunol. 2000;165:6193-6204.
22. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190:167-172. (Pubitemid 29011104)